Company intelligence / Profile preview

Magnus Metabolic

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Magnus Metabolic is a biopharmaceutical company focused on developing novel small molecule therapies for metabolic diseases, specifically targeting the thyroid hormone receptor beta (THR-beta). As part of the Magnus Life Science portfolio, the company leverages a 'hub and spoke' model to advance its research programs. Its lead program is centered on a liver-selective THR-beta agonist designed to treat nonalcoholic steatohepatitis (NASH) and related metabolic disorders. The company aims to provide potent therapeutic effects on liver fat and lipid profiles while minimizing systemic side effects typically associated with thyroid hormone activation.

Therapeutic areas: CardiovascularGastroenterologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Partnerships

University College London

Beyond the preview

Go deeper on Magnus Metabolic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Magnus Metabolic.

Explore the full profile